Ingredients with digestive health benefits are in high consumer demand. This is particularly true of probiotics. A recent Market Stats report indicated in 2018, the global probiotics market was estimated to be worth $49.4 billion; by 2023, it is projected to reach $69.3 billion, growing at a CAGR of 7%.
Recently, Ohly released a white paper that looks at the use of different peptide size fractions by Bifidobacteria. The white paper explains, “Together with other lactic acid bacteria (LAB), Bifidobacteria are commercially manufactured to satisfy customer demands for probiotic dietary supplements and dairy starter cultures , . Due to Bifidobacterium’s emergence as possibly one of the most important group of intestinal organisms with regards to human health, they currently have strong prominence in the market as probiotics . However, the process of growing Bifidobacteria in industrial settings has many challenges, as it is not always easy to achieve the optimal conditions for growth.”
Recently, LinkedIn featured this Ohly whitepaper in their Article Series, Pulse. The article offers “Insights Into the Use of Different Peptide Size Fractions,” and looks at how Ohly X-Seed® Peptone – having more small peptides than other peptones – performs.
The article and white paper could prove informative for manufacturers of yogurts and nutritional shakes. Click to see the LinkedIn article, and to get the link to the Ohly white paper.